New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 13, 2013
08:52 EDTSTJFDA announced Class I recall of St. Jude's Amplatzer delivery system
The FDA yesterday afternoon announced a Class I recall for St. Jude Medical's Amplatzer TorqVue FX Delivery System. The Amplatzer system is used to assist the attachment, loading, delivery, and deployment of Amplatzer Occluder devices. Amplatzer Occluder devices are used to close openings between the two upper chambers of the heart. The FDA stated that in a small number of cases, the distal end of the core wire of the TorqVue FX Delivery System could potentially fracture. The product may cause serious adverse health consequences, including death, the agency added.
News For STJ From The Last 14 Days
Check below for free stories on STJ the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 16, 2014
05:15 EDTSTJData shows PA pressure monitoring did not adversely affect kidney function
Subscribe for More Information
September 15, 2014
08:02 EDTSTJSt. Jude Medical announces launch of OPTISTM integrated system
St. Jude Medical announced the company has secured CE Mark and FDA clearance for the new OPTISTM Integrated System. The system is a departure from traditional, mobile cart-based diagnostic tools and advances percutaneous coronary intervention optimization via direct installation into a hospitalís cardiac catheterization laboratory, fully integrating optical coherence tomography and fractional flow reserve into PCI workflow.
07:45 EDTSTJCardiovascular Research Foundation to hold a conference
Transcatheter Cardiovascular Therapeutics: TCT 2014 to be held in Washington, D.C. on September 13-17 with some presentations being webcasted. Webcast Link
07:21 EDTSTJHeart Failure Society of America to hold annual meeting
Subscribe for More Information
September 13, 2014
18:16 EDTSTJSt. Jude Medical announces data from the EnligHTN III study
St. Jude Medical announced 12-month outcome data from the EnligHTN III study, which demonstrated a continuation of safe, rapid and effective treatment with the next-generation EnligHTN Renal Denervation System for patients with drug-resistant, uncontrolled hypertension. The results were presented during the 26th annual Transcatheter Cardiovascular Therapeutics scientific symposium.
September 12, 2014
15:03 EDTSTJSt. Jude Medical pausing Portico sales, implants, says Wells Fargo
Subscribe for More Information
September 8, 2014
07:26 EDTSTJMorgan Stanley to hold a conference
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use